Author: Guisado-Vasco, P.; González-Cortijo, L.; D’Errico, G.; Serrera-Alvarez, A.; Sotres-Fernandez, G.; GarcÃa-Coca, M.; Fernández-Sousa, J.M.; Luepke-Estefan, X.E.; López-MartÃn, J.A.; Jimeno, J.M.
Title: Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy Cord-id: pxldhmvr Document date: 2021_7_7
ID: pxldhmvr
Snippet: Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease (COVID-19) shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was n
Document: Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease (COVID-19) shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was negative for SARS-CoV-2 by day 14. Therapy was well-tolerated, and no COVID-19-related complications were observed. The patient was discharged 18 days after plitidepsin treatment having received a full second course of chemotherapy, with only a 1-week delay from the planned schedule.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date